Welcome to our dedicated page for Ramm Pharma news (Ticker: RAMMF), a resource for investors and traders seeking the latest updates and insights on Ramm Pharma stock.
RAMM Pharma Corp. operates in cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals, hemp-based products, nutrition, veterinary products and medical products. The company’s business includes a pharmaceutical and medical product operation in Uruguay, a GMP-certified formulation facility in Montevideo, and European hemp and CBD operations through subsidiaries including Canapar Corp. and HemPoland S.p.a. Z.o.o.
Company announcements commonly address shareholder meeting and voting matters, capital-structure disclosures, governance changes, operating and financial results, product development and approvals, and regulatory developments affecting hemp extracts, CBD and plant-derived cannabinoid products in Latin America and Europe.
RAMM Pharma Corp. has welcomed France’s new regulatory framework that permits the use of the entire hemp plant for CBD production, setting a THC limit of 0.3%. This legislation, effective from January 1, 2022, is expected to stimulate the CBD market in Europe, potentially influencing other EU countries to follow suit. RAMM is strategically positioned through its subsidiary, Canapar Corp., which operates the largest extraction facility in Europe. The EU CBD market was valued at €1.6 billion in 2020 and is projected to reach €8.7 billion by 2030.
RAMM Pharma Corp. (CSE: RAMM) has welcomed Germany's coalition government's agreement to legalize recreational cannabis, marking a pivotal moment for the European cannabis market. Already the largest medical cannabis market in Europe, Germany's market is projected to grow to €3.2 billion by 2025 from €403 million in 2021. RAMM's vertically integrated operations, particularly through its subsidiary Canapar Corp., position the company to capitalize on this growth with its advanced extraction facility and extensive product portfolio aimed at various market segments.
On September 15, 2021, RAMM Pharma Corp. (CSE: RAMM) announced the resignation of Mr. Sergio Martines from its board of directors. The company expressed best wishes for his future endeavors. RAMM Pharma is recognized for its work in plant-derived cannabinoid pharmaceuticals and operates a pharmaceutical business in Uruguay, with products approved for sale in several Latin American markets. The company also has a presence in Europe, focusing on CBD formulations and wellness products.
RAMM Pharma Corp. (CSE: RAMM) announced its intention to initiate a normal course issuer bid (NCIB) to repurchase up to 5% of its outstanding common shares. The NCIB is set to commence around July 12, 2021, and will last for one year. Purchases will occur on the Canadian Securities Exchange at market prices, with shares subsequently canceled. This move aims to address market valuation concerns regarding the company's shares.
RAMM is focused on cannabinoid pharmacology, operating in Uruguay and Italy, developing medically registered cannabinoid products and wellness items.
RAMM Pharma Corp. has successfully completed its acquisition of Canapar Corp. for approximately $26.1 million, issuing 21,778,752 RAMM Shares at a value of $1.20 per share. This acquisition positions RAMM in the expanding European cannabis market, leveraging Canapar's leading extraction facility and extensive distribution contracts. Canapar is expected to commence commercial sales soon, backed by significant supply agreements, enhancing RAMM's product offerings and market reach. The combined entity has a strong financial position with approximately $27.8 million in net working capital.
On June 14, 2021, RAMM Pharma Corp. (CSE: RAMM) announced that its acquisition of Canapar Corp. has been overwhelmingly approved by Canapar shareholders, with 98% voting in favor of the amalgamation. This transaction allows RAMM to acquire all common shares of Canapar not already owned. The closing of the amalgamation is anticipated around June 15, 2021, pending customary conditions. Canapar is a key player in CBD oil manufacturing in Europe, enhancing RAMM's product offerings in the growing plant-derived cannabinoid market.
RAMM Pharma Corp. announced a definitive acquisition agreement with Canapar Corp. on May 11, 2021, to acquire all outstanding Canapar shares for approximately 21.9 million RAMM shares, valued at $26.2 million. This strategic move positions RAMM to leverage Canapar's advanced extraction facilities and existing contracts in the European cannabis market, expected to grow significantly. RAMM previously held a 49% stake in Canapar and aims to enhance its product offerings and market presence.
RAMM Pharma Corp. (CSE: RAMM, OTC: RAMMF) has received federal approval from the Uruguayan Ministry of Agriculture for NettaVet™ 10% CBD Formulation, marking it as the world's first CBD veterinary medicine registered as a pharmaceutical product. This significant milestone allows for immediate production and sales, with the company also pursuing additional formulations and clinical trials for various animal conditions. The global pet CBD market is expected to reach USD $1.7 billion by 2025, indicating strong growth potential for RAMM's veterinary CBD products.
RAMM Pharma Corp. has launched commercial sales of its NettaPet™ CBD enriched dog food, produced under its subsidiary NettaLife. A total of 40 tons were produced, with over 50% already pre-sold, enabling nationwide distribution in Uruguay. The product includes premium ingredients without artificial additives, and comes in three formulations: Puppy, Adult, and Senior. The global pet food market is valued at $87.1 billion, with the pet CBD segment expected to reach $1.7 billion by 2025, highlighting strong growth potential in the industry.